Not Yet RecruitingNot Applicable

A Biopsychosocial-Based Multimodal Approach to Reducing the Risk of Delirium in ICU

Turkey (Türkiye)34 participantsStarted 2026-01-02

Plain-language summary

As part of this study, an intervention program aimed at preventing delirium in patients with subarachnoid hemorrhage treated in the intensive care unit will be implemented. Routine medical treatments, environmental adjustments, and a video-based communication program will be implemented to prevent delirium. In addition, basic body awareness training will be administered. Patients will be divided into two groups. One group will receive only the routine treatment program recommended by international guidelines (medical, enviromental adjustment and face-to-face interview etc.), while the other group will receive body awareness therapy addition to routine interventions.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged 18-85, * Patients scheduled for intensive care for at least 15 days due to SAH, unruptured intracranial aneurysm, and/or Arterovenous Malformation, * Those with a Mini Mental State Examination score of \> 24, * Those with a Glasgow Coma Score of 15, * Those with motor function in at least one extremity, * Those with pain \< 5/10 (according to the NRS) Exclusion Criteria: * Patients whose GCS fell to 14 or below for any reason during the study period; * Patients who developed septic shock and MODS; * Patients requiring endotrachial intubation and mechanical ventilation due to ARDS; * Those requiring vasopressors such as NE at a rate of \>0.25 mcg/kg/min; * Terminal cancer cases; * Patients with advanced chronic heart and lung failure and COPD; * Those with a METS (exercise capacity) of \<4; * Those with a history of dementia, Alzheimer's disease, or psychiatric illness; * Those with vision, hearing, or speech problems that would interfere with communication; * Those with a history of epilepsy;

What they're measuring

Charlson Comorbidity Index

Timeframe: Baseline

Charlson Comorbidity Index

Timeframe: 8th day after admission to ICU

Charlson Comorbidity Index

Timeframe: 15th day after admission to ICU

Mini-Mental State Examination Test

Timeframe: Baseline

APACHE II Score

Timeframe: Baseline

APACHE II Score

Timeframe: 8th day after admission to ICU

APACHE II Score

Timeframe: 15th day after admission to ICU

SOFA Score

Timeframe: Baseline

SOFA Score

Timeframe: 8th day after admission to ICU

Trial details

NCT IDNCT07249619

SponsorEmre Şenocak

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-01-02

Contact for this trial

Arzu Erden Güner, PhD

+90 506 248 26 80 arzuerden@ktu.edu.tr

View on ClinicalTrials.gov More Subarachnoid Haemorrhagic Stroke trials

Plain-language summary

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Charlson Comorbidity Index

Timeframe: Baseline

Charlson Comorbidity Index

Timeframe: 8th day after admission to ICU

Charlson Comorbidity Index

Timeframe: 15th day after admission to ICU

Mini-Mental State Examination Test

Timeframe: Baseline

APACHE II Score

Timeframe: Baseline

APACHE II Score

Timeframe: 8th day after admission to ICU

APACHE II Score

Timeframe: 15th day after admission to ICU

SOFA Score

Timeframe: Baseline

SOFA Score

Timeframe: 8th day after admission to ICU